BACKGROUND: We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year. METHODS: Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. RESULTS: Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention. CONCLUSIONS: Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%). (c) 2008 Wiley-Liss, Inc.
BACKGROUND: We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year. METHODS: Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. RESULTS: Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention. CONCLUSIONS:Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%). (c) 2008 Wiley-Liss, Inc.
Authors: Julie Wang; Joseph M Wiley; Ruth Luddy; Jay Greenberg; Michael A Feuerstein; James B Bussel Journal: J Pediatr Date: 2005-02 Impact factor: 4.406
Authors: Carolyn M Bennett; Zora R Rogers; Daniel D Kinnamon; James B Bussel; Donald H Mahoney; Thomas C Abshire; Hadi Sawaf; Theodore B Moore; Mignon L Loh; Bertil E Glader; Maggie C McCarthy; Brigitta U Mueller; Thomas A Olson; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Henry A Feldman; Ellis J Neufeld Journal: Blood Date: 2005-12-13 Impact factor: 22.113
Authors: Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel Journal: Br J Haematol Date: 2004-04 Impact factor: 6.998
Authors: Thomas Kühne; George R Buchanan; Sherri Zimmerman; Lisa A Michaels; Regina Kohan; Willi Berchtold; Paul Imbach Journal: J Pediatr Date: 2003-11 Impact factor: 4.406
Authors: Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter Journal: Blood Adv Date: 2019-11-26
Authors: V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher Journal: Pediatr Blood Cancer Date: 2009-07 Impact factor: 3.167